Baochuan Huang joined Frontera in May 2021 as Senior Vice President and Head of Frontera’s Manufacturing Site at Suzhou, China. Prior to joining Frontera, Baochuan had worked in the biotechnology and pharmaceutical field for 20 years, most recently as Vice President of CMC at Abpro Corp.
Baochuan received most of his professional trainings from international biopharmaceutical companies like Amgen, Shire and Baxter. He worked there for over 14 years and developed expertise in different areas of CMC, from cell line, process development, scale up and tech transfer, to GMP manufacturing, process validation and BLA applications. During his eight years at Amgen, he provided technical support to productions of hemophilia drug Aranesp, and led tech transfer of more than a dozen upstream processes from research to GMP manufacturing, including the block buster bone drug Prolia and diabetes drug Repatha.
From 2015 to 2021, Baochuan took CMC/Technical leadership roles at innovative smaller biotech TESARO, KINIKSA and ABPRO. He successful led cross-functional team to IND approvals of multiple protein drugs in US/EU in the field of oncology, inflammation and autoimmune disease. He is patent co-owner for multiple innovative molecules including commercial PD-1 antibody Dostarlimab, and Cobolimab which is in phase 3 clinical development.
Baochuan obtained BS/MS degree in Fermentation Engineering from Tianjin University of Science and Technology, China and Master’s degree in Chemical Engineering from Montana State University at Bozeman.